Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
-
REGULATORY MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
-
REGULATORY Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
-
REGULATORY Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
-
BUSINESS Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
-
REGULATORY DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
-
ORGANIZATION Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
-
BUSINESS Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
-
REGULATORY Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
-
COMMENTARY With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
REGULATORY MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig
November 11, 2024
-
BUSINESS Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake
November 11, 2024
-
ACADEMIA Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
-
REGULATORY Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
-
BUSINESS Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
-
ACADEMIA Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
-
ACADEMIA Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
-
REGULATORY Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
-
REGULATORY PMDA Opens US Office in Washington, D.C.
November 5, 2024
-
BUSINESS FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…